Author

Lukas Minder

University of ZurichORCID 0009-0002-0200-7938Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Andrea LaimbacheriD· 3 shared Gabriela KaniaiD· 3 shared Oliver DistleriD· 3 shared Przemysław BłyszczukiD· 3 shared Alicja BraczkoiD· 2 shared Barbara Anna Kutryb-ZająciD· 2 shared Dawid WnukiD· 2 shared Jarosław CzyżiD· 2 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

Andrea LaimbacherORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell BiologybioRxivPreprintAug 21, 2026

Dysferlin is a novel regulator of COMP-positive matrifibrocytes in heart failure

Ievgeniia Kocherova, Muriel Giger, Andrea Laimbacher…·Gabriela Kania

This study identifies dysferlin as an antifibrotic regulator that limits fibroblast differentiation and myocardial fibrosis in heart failure.

DOI 10.64898/2026.08.18.745492

humanbulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintAug 21, 2026

Lanifibranor (IVA-337) - a pan-PPAR agonist suppresses TGF-β1-induced cardiac fibrosis and rescues cardiomyocyte function

Milena Paw, Lukas Minder, Andrea Laimbacher…·Gabriela Kania

This study shows lanifibranor reduces TGF-β1-induced cardiac fibrosis and improves cardiomyocyte function in human models.

DOI 10.64898/2026.08.18.745414

humanexperimental assay

𝕏 PostBluesky

Cell BiologybioRxivPreprintAug 21, 2026

The dual PPAR-α/δ agonist elafibranor attenuates TGF-β1-induced cardiac fibrosis through redox-metabolic and bioenergetic reprogramming in human cardiac models

Milena Paw, Lukas Minder, Andrea Laimbacher…·Gabriela Kania

This paper shows that elafibranor reduces TGF-β1-induced cardiac fibrosis by improving redox-metabolic and bioenergetic processes in human cardiac models.

DOI 10.64898/2026.08.18.745425

humanbulk RNA-seq

𝕏 PostBluesky